SLC7A2 — Solute Carrier Family 7 Member 2 ( cationic amino acid transporter 2)

SLC7A2 — Solute Carrier Family 7 Member 2

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC7A2 — Solute Carrier Family 7 Member 2 ( cationic amino acid transporter 2)</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">mTOR</td>
<td>Regulation by mTORC1</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Cytokine-induced expression</td>
</tr>
<tr>
<td class="label">MAPK</td>
<td>Signaling downstream of NO</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Cross-talk</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

SLC7A2 (Solute Carrier Family 7 Member 2), also known as Cationic Amino Acid Transporter 2 (CAT2) or y+LAT2, is a membrane protein that mediates the transport of cationic amino acids across cell membranes[@closs1996]. This transporter plays crucial roles in various physiological processes, including nitrogen metabolism, nitric oxide synthesis, and immune responses. In the central nervous system, SLC7A2 has emerged as an important player in neuroinflammation and neurodegeneration[@sattler2020].

Gene Structure and Expression

SLC7A2 — Solute Carrier Family 7 Member 2

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC7A2 — Solute Carrier Family 7 Member 2 ( cationic amino acid transporter 2)</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">mTOR</td>
<td>Regulation by mTORC1</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Cytokine-induced expression</td>
</tr>
<tr>
<td class="label">MAPK</td>
<td>Signaling downstream of NO</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Cross-talk</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

SLC7A2 (Solute Carrier Family 7 Member 2), also known as Cationic Amino Acid Transporter 2 (CAT2) or y+LAT2, is a membrane protein that mediates the transport of cationic amino acids across cell membranes[@closs1996]. This transporter plays crucial roles in various physiological processes, including nitrogen metabolism, nitric oxide synthesis, and immune responses. In the central nervous system, SLC7A2 has emerged as an important player in neuroinflammation and neurodegeneration[@sattler2020].

Gene Structure and Expression

The human SLC7A2 gene is located on chromosome 8p22 and encodes a protein of approximately 630 amino acids with a molecular weight of around 70 kDa. The gene contains multiple exons and undergoes alternative splicing to generate distinct isoforms with different tissue distribution and substrate specificities[@devs1998].

Tissue Distribution

SLC7A2 exhibits a broad tissue distribution:

• Brain: Expressed in neurons, astrocytes, microglia, and endothelial cells of the blood-brain barrier[@bertz2014]
• Kidney: High expression in renal tubular cells[@silbernagl2003]
• Liver: Moderate expression in hepatocytes
• Lung: Detected in alveolar epithelial cells
• Immune cells: Activated macrophages and T-cells show increased expression[@simmons1996]

Isoforms

Two major splice variants have been characterized:

Protein Structure and Function

SLC7A2 belongs to the heterodimeric amino acid transporter (HAT) family. It requires interaction with a heavy chain (4F2hc/SLC3A2) for proper plasma membrane localization and function. The transporter operates as an exchange system, facilitating the bidirectional movement of cationic amino acids in exchange for neutral amino acids.

Transport Characteristics

• Substrates: L-arginine, L-lysine, L-ornithine, L-histidine
• Driving forces: Amino acid gradients, membrane potential
• Kinetics: Low-affinity, high-capacity transport
• Direction: Bidirectional (exchanger)

Role in Nitric Oxide Synthesis

SLC7A2-mediated arginine transport is critical for nitric oxide (NO) production by neuronal nitric oxide synthase (nNOS)[@schwartz2003]. Arginine serves as the substrate for nNOS, which generates NO as a signaling molecule in various neurological processes. Dysregulation of this pathway has been implicated in:

• Excitotoxicity
• Oxidative stress
• [Neuroinflammation](/mechanisms/neuroinflammation)

Role in Neurodegeneration

Alzheimer's Disease

Research has shown altered SLC7A2 expression in the brains of APP/PS1 transgenic mouse models of Alzheimer's disease[@liu2018]. The changes include:

• Upregulation in activated microglia surrounding amyloid plaques
• Altered arginine metabolism in affected brain regions
• Potential impact on NO signaling and neuroinflammation

Multiple Sclerosis

SLC7A2 has been implicated in multiple sclerosis pathogenesis through its role in immune cell function and neuroinflammation[@sattler2020]. The transporter influences:

• T-cell activation and proliferation
• Macrophage-mediated demyelination
• Cytokine production

Parkinson's Disease

While less studied, SLC7A2 may play a role in Parkinson's disease through:

• Regulation of arginine metabolism in dopaminergic neurons
• Modulation of neuroinflammation in the substantia nigra
• Potential effects on mitochondrial function

Expression in Brain During Inflammation

Inflammatory stimuli dramatically upregulate SLC7A2 expression in the brain[@williams2005]. This induction is mediated by:

• Pro-inflammatory cytokines (IFN-γ, TNF-α, IL-1β)
• Bacterial lipopolysaccharide (LPS)
• Activated microglia and astrocytes

Clinical Significance

Therapeutic Implications

SLC7A2 represents a potential therapeutic target for:

Drug Development

Several strategies are being explored:

• Small molecule inhibitors: Blocking excessive arginine uptake
• Gene therapy: Modulating transporter expression
• Substrate analogs: Developing competitive inhibitors

Interactions and Signaling Pathways

SLC7A2 interacts with multiple signaling pathways:

Animal Models

Knockout Studies

SLC7A2 knockout mice exhibit:

• Reduced NO production in response to inflammatory stimuli
• Altered arginine metabolism
• Impaired T-cell function
• Modified responses to brain injury

Transgenic Models

Overexpression studies reveal:

• Increased susceptibility to neuroinflammation
• Altered synaptic plasticity
• Modified behavioral phenotypes

Comparative Biology

SLC7A2 orthologs have been identified across species:

• Rodents: High sequence conservation with similar functional properties
• Zebrafish: Expressed in developing nervous system
• Drosophila: Functional homologs involved in neural development
• C. elegans: Orthologous transporters in neuronal cells

Research Methods

The study of SLC7A2 employs various approaches:

• Molecular biology: PCR, cloning, siRNA-mediated knockdown
• Biochemistry: Transport assays, immunoprecipitation
• Histology: Immunohistochemistry, in situ hybridization
• Physiology: Electrophysiology, behavioral testing
• Imaging: Live-cell imaging, PET scanning for arginine analogs

Future Directions

Key questions remaining include:

Pathway & Interaction Diagram

Interactive diagram showing SLC7A2's key relationships in the SciDEX knowledge graph (6 connections shown).

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Nitric Oxide in Brain](/mechanisms/nitric-oxide-brain)
• [Amino Acid Transporters](/proteins/amino-acid-transporters)
• [Genes Directory](/genes/)
• [Neurodegeneration Pathways](/diseases/neurodegeneration)

References

External Links

• [NCBI Gene: SLC7A2](https://www.ncbi.nlm.nih.gov/gene/6542)
• [Ensembl: SLC7A2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163866)
• [UniProt: O43292](https://www.uniprot.org/uniprot/O43292)
• [OMIM: 138894](https://www.omim.org/entry/138894)

Pathophysiological Mechanisms

Excitotoxicity and Glutamate Signaling

SLC7A2 plays an indirect but important role in excitotoxicity, a major mechanism of neuronal death in acute and chronic neurological disorders. The transporter modulates arginine availability, which influences nitric oxide production and subsequently affects NMDA receptor signaling.

Excitotoxicity involves:

SLC7A2 expression is altered in excitotoxic conditions, suggesting a compensatory or pathological role.

Oxidative Stress

The arginine-NO pathway is closely linked to oxidative stress in neurodegeneration. When arginine is transported into cells via SLC7A2, nNOS produces NO, which can either:

• Act as a protective signaling molecule at low concentrations
• Contribute to oxidative damage when overproduced

• Nitrosylation of proteins
• DNA damage
• Mitochondrial dysfunction
• Apoptotic signaling

Neuroimmune Activation

SLC7A2 is highly induced in activated microglia and infiltrating immune cells during neuroinflammation. This induction is mediated by:

• Interferon-γ (IFN-γ): Strong inducer of SLC7A2 transcription
• Tumor necrosis factor-α (TNF-α): Modulates transporter expression
• Interleukin-1β (IL-1β): Contributes to upregulation in astrocytes

• Increased arginine uptake in activated immune cells
• Enhanced NO production for antimicrobial defense
• Potential damage to surrounding neurons (bystander effect)

Therapeutic Strategies

Targeting SLC7A2 in Neurodegeneration

Several therapeutic approaches are being explored:

• Blocking excessive arginine uptake in hyperactive microglia
• Reducing NO-mediated damage in chronic inflammation

• Developing arginine analogs that compete for transport
• Modulating transport kinetics to normalize function

• Epigenetic modifiers to regulate SLC7A2 transcription
• MicroRNA-based approaches to knock down expression

Combination Therapies

SLC7A2 modulators may be combined with:

• Anti-inflammatory drugs: Reduce cytokine-mediated induction
• Antioxidants: Counteract oxidative stress
• Neuroprotective agents: Enhance neuronal survival

Regulatory Mechanisms

Transcriptional Regulation

SLC7A2 expression is tightly controlled at the transcriptional level:

• Promoter elements: Response to IFN-γ, TNF-α, and other cytokines
• Transcription factors: NF-κB, STAT1 involvement
• Epigenetic control: DNA methylation, histone modifications

Post-Translational Modifications

The transporter undergoes several modifications:

• Glycosylation: N-linked glycosylation affects trafficking
• Phosphorylation: Kinase regulation of transporter activity
• Ubiquitination: Controls protein stability and degradation

Trafficking and Localization

SLC7A2 localization is dynamically regulated:

• Plasma membrane: Functional transport activity
• Endosomal compartments: Regulation of transporter availability
• Cell junctions: Polarized distribution in epithelial/endothelial cells

Biomarker Potential

Diagnostic Applications

SLC7A2 expression may serve as a biomarker for:

• Neuroinflammatory activity: Detectable in CSF or imaging studies
• Disease progression: Correlation with clinical outcomes
• Therapeutic response: Changes with treatment

Monitoring Tools

• PET tracers: Arginine analogs for molecular imaging
• Blood biomarkers: Soluble forms detectable in peripheral blood
• CSF analysis: Direct measurement of transporter expression

Genetic Studies

Polymorphisms

Several SLC7A2 variants have been identified:

• Promoter polymorphisms: Affect transcription factor binding
• Coding variants: Alter transport kinetics
• Splice variants: Generate different isoforms

Association Studies

Genetic studies link SLC7A2 variants to:

• Neurological disease susceptibility: Altered risk for AD, PD, MS
• Treatment response: Predictive of therapeutic outcomes
• Age of onset: Modifies disease progression

Summary

SLC7A2 (CAT2/y+LAT2) is a critical cationic amino acid transporter with important roles in normal brain function and neurodegenerative disease. Through its regulation of arginine transport and nitric oxide synthesis, SLC7A2 influences neuroinflammation, excitotoxicity, oxidative stress, and synaptic transmission. While primarily recognized in the context of immune cell function, emerging evidence highlights its importance in neurons and glial cells during neurodegeneration. The transporter represents both a potential therapeutic target and a biomarker candidate for neuroinflammatory and neurodegenerative disorders.